MonoSol Rx Acquires U.S. Patent for Multifunctional Single Layer Film Drug Delivery Technology

Strengthens IP Leadership in Transmucosal Film Drug Delivery

Warren, NJ (Dec. 20, 2012) – MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced it has acquired U.S. Patent #8,241,661, entitled “Biocompatible Film with Variable Cross-Sectional Properties.” The patent, issued by the United States Patent and Trademark Office on August 14, 2012, and related foreign filings were acquired from inventors Richard and Joseph Fuisz. This strategic patent provides for the non-uniform distribution of components in the thickness direction of a single layer biocompatible film, thereby allowing for a multifunctional film to be developed in a single layer.

A. Mark Schobel, Co-President and Chief Executive Officer of MonoSol Rx, stated, “The addition of this patent to our IP portfolio reinforces MonoSol Rx as a leader and innovator in pharmaceutical film technology, and strengthens our proprietary film drug development capabilities from a compositional, method of manufacture, and drug performance perspective. This patent will be a significant IP asset to MonoSol Rx as we progress with our unidirectional transmucosal film drug delivery products and for those pharmaceutical companies who partner with us. This patented technology will also allow for the highly cost effective manufacturing of single layer multifunctional films where, currently, two or more film layers are necessary. Richard and Joseph Fuisz are leaders in the drug delivery space, and we are pleased to be the recipients of this ground-breaking technology. We are particularly pleased that the patent life for U.S. Patent #8,241,661 will extend well into 2031.”

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence. For press releases and other company information visit www.monosolrx.com.

* PharmFilm is a registered trademark of MonoSol Rx.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.
Phone
This field is for validation purposes and should be left unchanged.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Full name*
Email address*
Street Address*
City*
Zip Code*
Phone number*
Tell us how we can help your brand
Send me a kit
- Send me a PharmFilm® demonstration kit
I am interested in:
- Commercializing an existing product
- Commercializing a product in development
- Investment opportunities
To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive marketing updates regarding products and services from Aquestive Therapeutics.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
In what clinical trial are you interested?
To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

First Name*
Last Name*
Email Address*
Phone Number*
Role within the Epilepsy Community*
- Patient/Caregiver
- HCP
- Other
Tell us how we can assist you
- By providing my contact information, I agree that Aquestive Therapeutics (“Aquestive”) can use such information for its marketing database and that Aquestive and its agents may contact me by mail or email to provide information about Aquestive or its products or services. I understand that my contact information will not be sold to third parties, other than in the event Aquestive or its affiliates are sold. I understand that I have the right to opt-out of the database and have my information removed from the database at any time. Instructions on how to be removed from the database will be included in any future communications sent to me by Aquestive. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing lgsart@aquestive.com.

MonoSol Rx Acquires U.S. Patent for Multifunctional Single Layer Film Drug Delivery Technology

Please complete this form:

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Please complete this form:

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

Please complete our short form to speak with a business development specialist.